The content on this site is intended for healthcare professionals only
Dr Hurvitz presents data at San Antonio Breast Cancer Symposium 2016 from the phase II neoMONARCH trial of abemaciclib, a CDK4/6 inhibitor, as a single agent or combined with anastrozole for post-menopausal women with HR , HER- breast cancer.
The study found that, alone or with anastrozole, abemaciclib induced significantly greater cell cycle arrest, defined by reduced Ki67 expression.
Dr Hurvitz spoke more on CDK4/6 inhibition at an ecancer symposium in Copenhagen, here.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
Overview of the management of HER2-low breast cancer patients
